Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When you read thru the last two posts on this board and the latest Provectus Substack posting, you can not help being impressed with the potential of this company. Combine that with the `shareholder value' theme that Dom and Ed constantly align themselves with, I just can not see why we are trading for a couple dimes per share. Collaborations with Moffet Cancer, Univ of Miami/Bascom Palmer, Univ of Calgary, Univ of TN, HD Anderson and others sure think we are worth their time and effort. It feel like something will break in our favor soon. Yes much of this is all pre-trial, but progress is being made.
Thanks for the advice, getting any IV info is sketchy. Hope you and Wehalls keep posting here. Eye company organization should be disclosed soon, will be nice to have that $ commitment known . . . and behind us. A revenue stream in 12 - 16 months would be awesome.
Good trade. The sells are primarily from Saylor in a plan he announced at the beginning of the year running thru April 2024.
Coin Desk Article
I've owned CRMD in the past, I would have a lot of brushing up to do to get current. I do not feel very competent discussing the ongoing/current trials, others here are much more knowledgeable, but the Australian trial intrigues me the most. In the recent past,. there was talk about additional updates forthcoming from that trial and also the consideration of a Therapeutics Goods Administration (TGA - Australian version of the US FDA) PV-10 application, but have heard nothing since. Always felt like the Australian trial or UM ocular work would hit first. This morning's licensure agreement is positive but presently lacks the detail we need to forecast potential revenue flow or development costs for the new spinoff company; I'm sure further info will be available soon. Advancing any oncology trial to P3 status, therefore, is still a minimum of 1.5 years out from my take.
Maybe today breaks $1815 ATH . . . what a move this morning.
A close above $67.5k would be great support on the 21 day MA. Can't wait for halving to be behind us, feels like it is definitely holding this coin back.
PVCT has just improved from a lotto pick contender to long shot status with the Bascom Palmer Institute relationship (details yet to be announced). The Univ of Miami Bascom Palmer Institute agreement is the first step, of hopefully others, with far reaching clinical implications. IF the BPI agreement provides some much needed cash flow for the company in upcoming years (no licensure details as of yet), the oncological potential and timeline of PV-10 (PVCT's oncology development drug) could finally be elevated to the urgency and relevancy it so justly deserves. Present low n trials have produced substantial results for PV-10 but expensive trials of size/scope have long eluded us. Worse case, the BPI agreement at least legitimizes this company as a viable biotech partner.
BPI has said the new ophthalmological treatment using Rose Bengal has been ground breaking. Additional potential in oncology, wound/infection control, and even veterinary medicine lie ahead. Exciting times for this company thanks to PHR management who single handedly stabilized and refocused this once floundering company. Still a long way from profitability, plenty of hurdles remain ahead, odds remain against us, but finally there is a true light in the far distance.
BPI - Provectus
Nice showing of some strength today. BTC down, MSTR slightly green.
Wrong board, sorry.
Bitcoin actually holding rather well.
Can't watch, need to turn off the screen . . . . and to think there could be months ahead of more of this.
MSTR up 13%. Thank you BTC!!!
0.6% move on Bitcoin generating a 13% move in MSTR when posted. No published news/articles as of today yet; most recent articles refer to inside selling of director and Saylor. When the dam finally breaks for bitcoin (breaking the $53k area), this is going to shoot violently higher.
Unbelievable, and there is more to come in the months ahead. My $1k shares I bought two years ago not looking as awful any longer. This is my second largest holding, and I just keep buying more as I am able. Feels good to have a huge winner in the portfolio. Go Saylor, go MSTR!!!
Sorry to hear that. Took a major hit myself when Voyager became an indirect victim to FTX. I'm in MSTR for the same reason as you. With the premium manipulation by GBTC, I believe MSTR is a better or equivalent value without the required K1 tax filings.
I agree with you. Been buying for several years on a leap of faith, even include 45 shares @ $1k+ from a couple of years ago. I feel the FASB new ruling on cryptocurrency will benefit this company enormously. Their balance sheet will certainly be cause for a higher market cap alone. I do not own enough MSTR. 2024 could be incredible.
Why is this decoupling from Bitcoin??? Love the results, just want to understand why. Happening in all mining stocks but not so much in other BTC treasury stocks like SQ and PYPL.
This stock should be higher than 50 cents at a bare minimum. Recent data read outs, today's news, strong insider support are ample support for higher prices. Don't understand why we are down today on a positive headline.
Great news, thank you, was hoping for above average results; PV-10 certainly did not disappoint. Realistically, however, I do not see this doing anything for the price other than today's bump. Some second tier biotech has to be getting interested, however, this has to be compelling to them on so many levels as an affordable investment/partnership. Big pharma does not see the financial opportunity in the PVCT approach; more interested in maintaining their reoccurring price gouging regimens.
We are making progress thank goodness, just do not think this data set will be our start. I believe some collaborative news will eventually be forthcoming, just don't think this release is enough. Added on the last dip to $0.08, will do so again if the opportunity presents itself. The ocular and veterinary products might be the first to make noise.
Thank you for your write up Wehalls, I remain overall encouraged even though I am a bit deflated that the TGA route seems to be rapidly dwindling. More likely, it appears to be a probable dead end since we would not likely put limited resources into a foreign drug approval agency if a `fast track' avenue is not an option for us.
I always thought the ocular route with Miami would be our first revenue producer despite the statement that Management is "trying to stay focused and putting everything on the back burner that is not related to their current oncology trials". I forgot about the animal/pet possibility, glad to hear that is moving forward, I honestly thought that had great merit as well.
Don't know what to think about the reverse stock split, I do not recall one company off hand that has used it successfully; I realize there are certainly outliers. Sounds like Ed and Dom are not to concerned about financing, that is certainly positive news. And having potential investors helping out with clinical trials is very positive. I like the idea that any financial decision they make has at least some consideration for the shareholders. PHR has been wonderful to us so far, I think they are a stand up management team, no one else would finance a company like they do by buying the convertible shares over market value. Would just like to see some traction in clinical outcomes; just seems like a consistent one foot forward, another step backwards approach.
Appreciate your write-up, I remain pretty upbeat about the company despite knowing it remains a long shot for commercial success (inherent with the industry). One can dream though, and patients may one day may have medical options that can truly extend and improve quality of life thanks to PVCT. Thank you for your efforts.
Been selling puts on this run but would have been much better off just buying shares and turning off the computer. Nothing wrong with having a little safety at these levels, come Tuesday, you may consider it a superstar move.
Strong today with decent volume at midday. New 20 day high. Wants to push higher.
Yet another bounce off of $0.10 support. Stock is reacting well after recent Dec highs. Good call on support Wehalls, I have an order in at $0.10, seems like that is the new line in the sand. Saw on the other board that Pershing bought additional shares ($125k of $0.286 convertible notes). That certainly shows conviction. Still a long wait ahead but exciting nonetheless.
Our little bio is still in the holiday spirit, closed even in a broadly down market. 2-0-1 for the new year, nice batting average. Volume has declined depreciably though, fortunately with little price movement. Must mean not many motivated sellers. Still need a few more shares, I should have ample opportunities in the months ahead. This year I feel price appreciation will be on our side.
PVCT's tweets this morning listed some superior PV-10 drug attributes, differentiating themselves from miRNA research and method of actions, that I would have thought would be more likely provided when in direct meetings with a bp to potentially secure their interest and financing.
By going public with it like we did, does that flag that no credible discussions are ongoing? It seems to me that one would not go public with that info unless they are purposely trying to mass market themselves to the bp community at large . . . . meaning promising discussions may not be currently underway with a specific bp. Do you have a read on the matter?? I'm probably getting to wrapped up over nothing, just do not want the momentum to stall. I'm hoping some clinical phase announcement is only a couple of quarters out at most.
Good call. Wild gyrations again in the last 20 minutes of trading. Wehall's 10 cent base nicely held yet again as well. Things looking promising, but it may be months off (hopefully shorter) before we get some meaningful clinical trial discussions going.
Volume back down to pre-news levels, now we wait. 10 cent base continues to build out, hopefully it holds. Cautiously optimistic for the upcoming year. Overall market looking like it will be fighting headwinds well into first quarter.
For the second day in a row, the stock closed relatively flat by session end. Today was the exact opposite of yesterday, today's mid-session loss recovered in the last 15 minute segment with the highest volume of the day, as well as the biggest green candle of the session. Yesterday's trading was the exact opposite; giving away mid-afternoon gains with the tallest red candle combined with the highest candle volume, all in the last half hour of trading. Low 8 cents the past two days held up. Don't quite understand what all the last minute price/volume market fervor is all about. Today's volume was the second weakest of the last ten days, beating only yesterday's total volume (per trading view).
Just musing out loud where the new price channel range could possibly settle in for this new period; do we see 7 cents for the low while we await further news? If so, that would still be a decent improvement over our last hibernation zone of 4 cents. I need to be more patient this time in lowering my cost per share. Just feel this company has a realistic chance for success and I want to make sure I have a decent seat; management has demonstrated their opinion with recent purchases. We will undoubtedly learn a considerable bit about this company in 2023, hopefully for the best.
Feeling positive something big just over the horizon. Maybe the Australian TGA will expand limited PV-10 use, or possibly a big pharma starts nosing around, or the Univ of Miami ocular licensure takes off, or even the possible reverse split gives us a bump. But 2023 looking promising in my book. Its been a long wait, hopefully this upcoming year will show some serious momentum. The limited study results released this past week sure were encouraging, patients the true beneficiaries. Makes me feel like holding long term may not be so bad an idea after all.
Nice move today. Pershing buying more shares. Something is up, volume is multiples of avg daily. Must be the update to be presented in Italy next week. Might be a nice move in store for us.
Diluting stock at the lowest level? Makes no sense unless the company is panicked things can can get worse, like sub $1. We may not see $4 again, even with a $60k bitcoin.
Over $5 for the 2nd day in a row, sure hope the current momentum sticks for awhile. The recent Edgecast acquisition/merger is getting some praise in the analyst community. Essentially acquired at 1.0 times Edgecast annual revenue. Yahoo will hold 31% of the retitled company - Edgio. Think they could have come up with a better name though imo. The common share transaction tells me that Yahoo has faith in the direction/merits of the new company.
https://www.streetinsider.com/Corporate+News/Limelight+Networks+(LLNW)+Acquires+Yahoos+Edgecast+for+$300M+in+Stock/19734296.html
This is getting exciting, the new management team is already setting a promising pace.
My belief is the EdgeCast acquisition has greatly increased LLNW footprint into scalable edge computing which will result in immediate eps improvement even with the additional shares that will be issued.
https://www.streetinsider.com/Corporate+News/Limelight+Networks+(LLNW)+Acquires+Yahoos+Edgecast+for+$300M+in+Stock/19734296.html
per article: "The combination will create a globally scaled, edge enabled software solutions provider with pro forma 2021 revenue of more than $500 million across cloud security and web applications, content delivery and edge video platform."
Seems more like a merger to me: "Yahoo will receive approximately 72.2 million shares of Limelight common stock, subject to customary closing adjustments, and will own approximately 31.9% of the combined company at closing."
Although still a long shot, and far from clinical trial derived results, PVCT sure has some shots on goal. Ophthalmology applications and/or veterinary medicine offshoots alone could provide some much needed cash flow for attempting to hunt down the main prize. Some biotech somewhere has to be taking notice.
This stock has come a considerable way since breaking that $3.20 support back in December. Just want it to consolidate a bit here and somehow hold $4.00, don't want it to retest $3.80. Regardless, the management change seems to have worked, feel like there will continue to be progress in the near term. With the great tech stock earning reports tonight, maybe a bit can spill into the edge computing/infrastructure sector.
Company has promise, no doubt about that. If this thing ever makes a break-out move, can't imagine how high it may go. Nonetheless, the stock is still a lottery ticket type investment. Their patent protection over Rose Bengal concerns me most. Not sure what type of `moat' they have for legal protection. Even if Rose Bengal is proven to be a highly effective (which I believe it will be proven to be), what prevents other BP's to just make clinical grade generic PV10 themselves?
The many potential uses of this beneficial drug is so impressive, for patient and investor sakes, I hope they are successful.
Feels like the recent upside still has some wheels. If it could somehow break a recent top at $61 before earnings, that would be ideal. Still have faith we see $70's in the mid-future, but that is a sizeable climb from here. Need a strong earnings report in November.
Thanks for your perspective, I have been deliberately avoiding news/status of this stock for awhile; I own a bit. I also believe the much needed new CEO could be a catalyst for the price; did not realize they had a recent acquisition. I just feel that FSLY and LLNW are in a fabulous market segment and will not only recover but resume accelerated growth trends.
Can we see $4.50 by end of May on this one?? Has been a slow steady climb since you spotted the candlestick pattern.
The price movement in this stock sure justifies the 1.45 beta. High volatility, but nice overall trend. Big price swings.